Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Babu, Subramanian; Chetal, Gaurav; Kumar, Sudhir

doi:10.7314/apjcp.2012.13.5.1737

Cited by 51 publications

(37 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic inflammation plays an important role in various aspects of cancer involving cancer initiation, promotion, progression, metastasis and clinical features (Balkwill et al, 2001;Mantovani et al, 2008;Babu et al, 2012) which has gradually attracted the attention of relevant researchers worldwide due to the rising incidence of cancer in public. Cancer-related inflammation has been recognized as the seventh hallmark of cancer (Colotta et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies

Guo

Pan²,

Du³

et al. 2013

Asian Pacific Journal of Cancer Prevention

128

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies

Guo

Pan²,

Du³

et al. 2013

Asian Pacific Journal of Cancer Prevention

128

View full text Add to dashboard Cite

“…The source of CXCL12 in the liver is still not entirely clear but recent studies identified HSEC, Kupffer cells (59), and activated HSC (60) as potential producers of this chemokine. Another CXCR4-interacting cytokine is the macrophage migration inhibitory factor (MIF) that has been implicated in various stages of cancer progression (61) and recently identified as a potential marker for CRC liver metastasis (62). CCL20/CCR6 were also implicated in CRC liver metastases, based on a strong association between the CCR6 staining intensity in primary CRC specimens and the development of synchronous liver metastases (63).…”

Section: Chemokine/chemokine Receptors Recruit Circulating Tumor and mentioning

confidence: 99%

The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications

et al. 2013

View full text Add to dashboard Cite

The liver is host to many metastatic cancers, particularly colorectal cancer, for which the last 2 decades have seen major advances in diagnosis and treatment. The liver is a vital organ, and the extent of its involvement with metastatic disease is a major determinant of survival. Metastatic cells arriving in the liver via the bloodstream encounter the microenvironment of the hepatic sinusoid. The interactions of the tumor cells with hepatic sinusoidal and extrasinusoidal cells (endothelial, Kupffer, stellate, and inflammatory cells) determine their fate. The sinusoidal cells can have a dual role, sometimes fatal to the tumor cells but also facilitatory to their survival and growth. Adhesion molecules participate in these interactions and may affect their outcome. Bone marrowderived cells and chemokines also play a part in the early battle for survival of the metastases. Once the tumor cells have arrested and survived the initial onslaught, tumors can grow within the liver in 3 distinct patterns, reflecting differing host responses, mechanisms of vascularization, and proteolytic activity. This review aims to present current knowledge of the interactions between the host liver cells and the invading metastases that has implications for the clinical course of the disease and the response to treatment. Cancer Res; 73(7); 2031-43. Ó2013 AACR.

show abstract

“…Systemic inflammatory response (SIR) is an important prognostic factor for survival in various types of cancer (5,6). Neutrophils, platelets, lymphocytes and albumin play a prominent role in cancer-related inflammation.…”

Section: Introductionmentioning

confidence: 99%

Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy

Haraga

Nakamura

Omichi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. This study investigated whether pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and prognostic nutritional index (PNI) are prognostic factors in patients with cervical cancer who undergo concurrent chemoradiotherapy (CCRT) and radiotherapy (RT). A total of 131 patients who underwent CCRT and RT for cervical cancer were retrospectively investigated and the correlations of NLR, PLR and PNI with clinical parameters and prognosis were assessed in CCRT and RT. The CCRT and RT groups had a median progression-free survival (PFS) of 41.82 and 24.72 months, respectively, and an overall survival of 49.70 and 29.56 months, respectively. At a cut-off value of NLR≥2.85, the PFS and OS in patients with higher NLR undergoing RT were significantly shorter compared with those in patients with lower NLR (P=0.029 and P=0.017, respectively). At a cut-off value for PNI of ≤48.55 in patients undergoing CCRT and ≤45.80 in patients undergoing RT, the PFS and OS in patients with lower PNI were significantly shorter compared with those in patients with higher PNI (PFS and OS with CCRT, P<0.001 and P<0.001, respectively; PFS and OS with RT, P=0.002 and P=0.008, respectively). Multivariate analyses also identified low PNI as an independent prognostic factor for PFS and OS in patients receiving CCRT. Therefore, low PNI was shown to predict poor prognosis in patients with cervical cancer.

show abstract

Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Cited by 51 publications

References 96 publications

Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies

Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies

The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications

Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy

Contact Info

Product

Resources

About